Ensysce Biosciences Inc (ENSC)
0.5586
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
0.559
0.00 (0.00%)
After-Hours: 20:00
Ensysce Biosciences Cash from Operations (TTM): -10.78M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -10.78M |
September 30, 2023 | -12.27M |
June 30, 2023 | -16.73M |
March 31, 2023 | -18.06M |
December 31, 2022 | -17.89M |
Date | Value |
---|---|
September 30, 2022 | -18.36M |
June 30, 2022 | -15.47M |
March 31, 2022 | -11.16M |
December 31, 2021 | -8.242M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-18.36M
Minimum
Sep 2022
-8.242M
Maximum
Dec 2021
-14.33M
Average
-15.47M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Processa Pharmaceuticals Inc | -8.063M |
Omeros Corp | 74.73M |
Relmada Therapeutics Inc | -51.66M |
NeuroBo Pharmaceuticals Inc | -10.80M |
MAIA Biotechnology Inc | -13.07M |